Funding news · Oct 2, 2026
BioOra Raises NZ$30M Series A for Automated CAR-T Manufacturing
BioOra Closes NZ$30M Series A
BioOra, a New Zealand biotechnology company developing automated manufacturing capability for next-generation CAR-T cell therapies, has raised NZ$30 million in Series A funding. The round was announced on October 2, 2026.
What BioOra Does
BioOra is focused on building sovereign, automated manufacturing capability for next-generation CAR-T cell therapies. CAR-T therapies reprogram a patient's own immune cells to target cancer.
The company's lead therapy, Atla-cel, is in development for relapsed/refractory diffuse large B-cell lymphoma.
Beyond the therapy itself, BioOra is constructing a manufacturing facility in Christchurch. The facility is intended to serve hundreds of patients a year across the Southern Hemisphere.
Company Background
BioOra was founded in 2021 through a collaboration between the Malaghan Institute of Medical Research and Bridgewest Ventures NZ. The company is based in New Zealand.
The Round at a Glance
| Detail | Value |
|---|---|
| Round type | Series A |
| Amount | NZ$30,000,000 |
| Currency | NZD |
| Announced | October 2, 2026 |
| Stage | Series A |
Investors
- Bridgewest Ventures
- Cincinnati Children's Hospital Medical Center
No lead investor was disclosed with the announcement.
Why It Matters
CAR-T therapy has transformed treatment for certain blood cancers, but access and manufacturing capacity remain significant constraints — particularly outside major cell-therapy hubs. BioOra's strategy addresses both sides of that equation: a clinical-stage therapy in Atla-cel and an automated manufacturing build-out designed to supply the Southern Hemisphere.
The Christchurch facility is central to that strategy. By targeting capacity for hundreds of patients per year, BioOra is positioning manufacturing as a core part of its value proposition rather than an outsourced function.
Acquisition Angle
BioOra sits at the intersection of cell therapy development and automated manufacturing — two areas of intense strategic interest for pharmaceutical companies, CDMOs, and investors building regional cell-therapy capacity.
Key considerations for potential acquirers include:
- Lead asset — Atla-cel for relapsed/refractory diffuse large B-cell lymphoma.
- Manufacturing infrastructure — a Christchurch facility under construction, intended to serve hundreds of patients annually across the Southern Hemisphere.
- Sovereign capability — automated manufacturing positioned as regional cell-therapy infrastructure.
- Founding collaboration — established through the Malaghan Institute of Medical Research and Bridgewest Ventures NZ.
- Investor base — Bridgewest Ventures and Cincinnati Children's Hospital Medical Center participating in the Series A.
What's Next
BioOra has not disclosed specific allocation plans for the NZ$30 million. The Series A, announced October 2, 2026, provides capital to support its lead therapy program and the build-out of its Christchurch manufacturing facility.